Inspira Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market HYLA blood sensor intends to reduce the need for actual blood samples

Inspira Technologies Develops a

Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market

HYLA blood sensor intends to reduce

the need for actual blood samples to be taken from patients

Ra'anana, Israel- Inspira Technologies OXY B.H.N.

Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support

technology company, revealed the development of the HYLA blood sensor. Without the need to take actual blood samples from patients,

Inspira's non-invasive optical blood sensor is being designed to perform real-time and continuous blood monitoring to alert physicians

of immediate signs of changes in a patient's clinical condition. The HYLA blood sensor is targeting the potential $2.5 billion Point

of Care testing, ABG (Arterial Blood Gas) analyzer market.

Optical sensor based on machine-learning algorithms

The non-invasive HYLA blood sensor is being developed by a team of

cyber-warfare specialists who formerly served in the Israeli Defense Forces' elite cyber-attack special forces. The HYLA blood sensor

is being designed as a new platform based on key technologies being developed for Inspira's ART system, designed to reduce

the need for invasive mechanical ventilation. Like the ART system, the HYLA blood sensor is designed to minimize the need for invasive

medical procedures with the intention of reducing risks, complications and costs.

HYLA blood sensor- designed to provide real-time continuous

measurements of key blood parameters

Expanding Market Growth Opportunities

The HYLA non-invasive blood sensor is attached

to the outer walls of a tube that has blood flowing through it. The HYLA blood sensor may have broad application potential, benefiting

patients undergoing procedures including intensive care unit (ICU) monitoring (approximately 40% of patients have a standard arterial

line), Invasive Mechanical Ventilation, Extracorporeal Membrane Oxygenation (ECMO), Dialysis and Cardiopulmonary bypass. Targeted patient

populations can potentially include those suffering from acute respiratory failure, cardiac failure, pneumonia, acute kidney injury (AKI),

as well as patients undergoing open-heart surgery.

Real-time patient monitoring can potentially

Currently, in order to identify changes in a patient's medical

condition, frequent invasive blood tests are needed. As a non-invasive real-time blood sensor, the HYLA is expected to reduce the need

for frequent invasive blood tests.

The HYLA blood sensor is expected to continuously measure several key

indicators such as the levels of partial oxygen and carbon dioxide pressures, known to be precise indicators of health disorders and patient

Dagi Ben-Noon, Inspira Technologies'

Chief Executive Officer, stated:

"Inspira Technologies has set out to change

the way we monitor patient health. Today, hospital patients are reliant on physicians manually monitoring their health condition with

invasive blood tests, as much as several times a day. We believe that the HYLA blood sensor has the potential to change patient experience

and outcomes, through the non-invasive blood sensor, that is intended to perform real-time and continuous blood monitoring, with the intention

of alerting physicians of changes in a patient's clinical condition that could potentially save lives."

This technology has not been tested or used in humans and is subject

to regulatory approval.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in

the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (ART), designed to rebalance

patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment

while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically

induced coma. The Company's product has not yet been tested or used in humans and has not been approved by any regulatory entity.

For more information, please visit our corporate website:

Forward-Looking Statement Disclaimer

US Investor Relations

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

Copyright 2018-2022 Inspira Technologies OXY B.H.N. LTD., All